3374-22-9Relevant articles and documents
MODIFIED INTERLEUKIN-7 PROTEINS AND USES THEREOF
-
, (2021/10/22)
Provided are a modified IL-7 polypeptide and a fusion protein containing the modified IL-7 polypeptide. The fusion protein of the modified IL-7 includes: a first domain containing an interleukin-7 polypeptide; a second domain containing an oligopeptide having 1 to 10 amino acid residues (with proviso that the second domain excludes the oligopeptide consisting of methionine and/or glycine); and (c) a third domain which prolongs the half-life of the IL-7 fusion protein. The modified IL-7 polypeptide is composed of the (a) first domain and the (b) second domain. The modified IL-7 polypeptide and the fusion protein are expressed in a higher yield than the wild-type IL-7 and shows increased stability.
Cysteine Chemistry in Connection with Abiogenesis
Bridoux, Maxime,Ceccarelli, Cecilia,Shalayel, Ibrahim,Vallée, Yannick,Vazart, Fanny,Youssef-Saliba, Sparta
supporting information, (2020/05/18)
Theoretical and experimental work has been conducted about possible prebiotic syntheses of cysteine. Activated derivatives of this amino acid can oligomerize and polymerize to afford various poly-thiazolines and cysteine-rich chains.
T Cells with Increased Immunosuppression Resistance
-
, (2018/02/06)
This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment